These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20134488)

  • 41. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
    Tursi A; Papa A; Danese S
    Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Faecal calprotectin in colonic diverticular disease: a case-control study.
    Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F
    Int J Colorectal Dis; 2009 Jan; 24(1):49-55. PubMed ID: 18941760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is mesalazine treatment effective in the prevention of diverticulitis? A review.
    Stefanelli G; Viscido A; Valvano M; Vernia F; Frieri G; Ashktorab H; Latella G
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8164-8176. PubMed ID: 32767345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Management of Patients With Diverticulosis and Diverticular Disease: A Survey From the 2nd International Symposium on Diverticular Disease.
    Tursi A; Picchio M; Elisei W; Di Mario F; Scarpignato C; Brandimarte G
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S97-S100. PubMed ID: 27622380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
    Picchio M; Elisei W; Tursi A
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):291-297. PubMed ID: 30240473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Colonic diverticular disease. Treatment and prevention.
    Gargallo Puyuelo CJ; Sopeña F; Lanas Arbeloa A
    Gastroenterol Hepatol; 2015 Dec; 38(10):590-9. PubMed ID: 25979437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Primary-Care Interventional Model on the Diverticular Disease: Searching for the Optimal Therapeutic Schedule.
    Campanini A; De Conto U; Cavasin F; Bastiani F; Camarotto A; Gardini L; Geremia A; Marastoni C; Missorini C; Quarantelli E; Sassi U; Scarabello F; Dal Bo N; Riccò M; Grillo S; Landi S; Di Mario F
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S93-6. PubMed ID: 27622379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rifaximin for inflammatory bowel disease.
    Guslandi M
    Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
    [No Abstract]   [Full Text] [Related]  

  • 49. [Diverticulitis : Domain of conservative or drug therapy?].
    Böhm S; Kruis W
    Internist (Berl); 2017 Jul; 58(7):745-752. PubMed ID: 28608124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease.
    Pietrzak AM; Banasiewicz T; Skoczylas K; Dziki A; Szczepkowski M
    Pol Przegl Chir; 2020 Apr; 92(2):22-28. PubMed ID: 32312914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rifaximin and Crohn's disease: a new solution to an old problem?
    Day AS; Gearry RB
    Dig Dis Sci; 2010 Apr; 55(4):877-9. PubMed ID: 20155320
    [No Abstract]   [Full Text] [Related]  

  • 52. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
    Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
    Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?
    Purslow C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):263. PubMed ID: 22816171
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of Diverticular Disease With Aminosalicylates: The Evidence.
    Barbara G; Cremon C; Barbaro MR; Bellacosa L; Stanghellini V
    J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S60-3. PubMed ID: 27622369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rifaximin: a new approach to the treatment of travelers' diarrhea. Introduction.
    Ericsson CD
    J Travel Med; 2001 Dec; 8(Suppl 2):S25. PubMed ID: 12186669
    [No Abstract]   [Full Text] [Related]  

  • 56. Rifaximin: a new approach to the treatment of travelers' diarrhea. Conclusion.
    Ericsson CD
    J Travel Med; 2001 Dec; 8(Suppl 2):S40. PubMed ID: 12186673
    [No Abstract]   [Full Text] [Related]  

  • 57. [Follow-up observation of intestinal Behçet disease treated with salazosulfapyridine and mesalazine for 8 years and 9 months].
    Kitauchi S; Ohata H; Kuroda R; Hirose M; Sakaguchi A; Nishi S; Nishioka S
    Nihon Shokakibyo Gakkai Zasshi; 1998 Feb; 95(2):140-4. PubMed ID: 9513566
    [No Abstract]   [Full Text] [Related]  

  • 58. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
    Tursi A; Elisei W; Brandimarte G; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E
    Neurogastroenterol Motil; 2012 Sep; 24(9):836-e396. PubMed ID: 22680042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical treatment of colonic diverticular disease: are we sure the aim is right?
    Bassotti G; Villanacci V
    Intern Emerg Med; 2012 Apr; 7(2):97-8. PubMed ID: 21424908
    [No Abstract]   [Full Text] [Related]  

  • 60. Colonic diverticular disease.
    Simpson J; Spiller R
    Clin Evid; 2003 Jun; (9):478-87. PubMed ID: 12967373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.